Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (Nasdaq: ENLV) has randomized 135 patients and administered their first Allocetra injection in its Phase 2b knee osteoarthritis trial.
The study plans to enroll 182 patients aged 64 and older with moderate-to-severe age-related symptomatic primary knee osteoarthritis. Recruitment continues in the United States, Denmark and Poland. Enlivex expects topline six-month data by mid-2027.
The randomized, double-blind, placebo-controlled trial evaluates safety and efficacy of injections into the knee joint. Key efficacy measures compare changes in pain and function with placebo at three and six months; additional measures assess quality of life and functional mobility. The study follows Phase 1/2a results described as positive by Enlivex, which supported FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted in July 2026.
Enlivex (ENLV) received a Nasdaq delisting notice over its failure to meet the minimum bid price requirement and plans to appeal.
The notice, dated October 26, 2026, cites closing bids below $1.00 during the 30 consecutive business days prior to October 22, 2026. A reverse split within the preceding 12 months makes Enlivex ineligible for a 180-day compliance period. A timely hearing request would stay suspension or delisting pending the appeal hearing, with shares continuing to trade on the Nasdaq Capital Market during that period.
A 1-for-16 reverse split becomes effective October 27, 2026. Enlivex gives regaining listing compliance and supporting its appeal as the reasons for the split; continued listing after the hearing is not assured.
Enlivex (ENLV) will implement a 1-for-16 reverse share split effective October 27, 2026, when split-adjusted trading begins on The Nasdaq Capital Market.
Every 16 ordinary shares will become one. Issued and outstanding ordinary shares will decrease from 24,511,905 to approximately 1,531,995, subject to adjustments for fractional-share rounding. Outstanding warrants and options will receive proportionate adjustments to their exercise prices and underlying share counts. Shareholder ownership percentages will remain unchanged except for fractional-share rounding adjustments; voting rights and other ordinary-share terms will not change.
Enlivex (Nasdaq: ENLV) announced an immediately effective cost reduction plan to focus resources on its Phase 2b Allocetra knee osteoarthritis trial.
The company is winding down all research and development unrelated to the trial and reducing its workforce by approximately 60%. Management salaries will fall 20%, and the CEO’s salary will fall 40%. Enlivex expects the plan to substantially reduce cash burn and expects six-month topline trial data by mid-2027.
The trial evaluates patients aged 64 and older with moderate-to-severe age-related symptomatic primary knee osteoarthritis. This population received FDA Regenerative Medicine Advanced Therapy designation in July 2026. The completed Phase 1/2a trial showed statistically significant pain and function improvements versus placebo at three and six months in the age-related primary osteoarthritis responder population, with a favorable safety profile.
Enlivex (ENLV) terminated a previously announced securities purchase agreement with the Rain Foundation under which Rain had agreed to buy 66,666,667 ordinary shares in a private placement using RAIN tokens, subject to shareholder approval.
The company exercised its contractual termination rights, so it will not complete the contemplated private placement and will not seek shareholder approval for the transaction. Enlivex continues to describe itself as a quality longevity company advancing Allocetra™, a clinical-stage immunotherapy for age-related inflammatory conditions such as osteoarthritis, alongside a prediction markets treasury strategy built around the Rain protocol.
Enlivex (Nasdaq: ENLV) reported that, as of July 29, 2026, trading volume on the Rain protocol reached $860 million, representing 622% month-over-month growth in July 2026 versus June 2026. The update relates to Enlivex’s RAIN token-based prediction markets treasury portfolio.
According to Enlivex, the Rain Foundation currently projects Rain protocol trading volumes of $1.3 billion in 2027, $12 billion in 2028 and $33 billion in 2029. At those levels, Rain Foundation expects gross fees of $49 million, $436 million and $1.2 billion, and net buy-and-burn allocations of $24 million, $216 million and $600 million, respectively. Enlivex highlights public, unaudited mark-to-market treasury metrics on its website and notes that detailed RAIN token data is available on CoinMarketCap.
The company reiterates its dual strategy: advancing Allocetra, a clinical-stage immunotherapy targeting age-related osteoarthritis, while maintaining exposure to the decentralized prediction markets ecosystem through the Rain protocol.
Enlivex (Nasdaq: ENLV) will host a live investor webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time. Management plans to discuss the rationale and intended use of proceeds for its recently announced private placement, the status and long-term strategy of its Rain protocol-based RAIN treasury, and recent clinical progress of Allocetra™, including its new Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for symptomatic knee osteoarthritis in patients aged 64 and older. Investors can register at the provided RedChip webinar link.
Enlivex (Nasdaq: ENLV) entered into a securities purchase agreement with a single institutional investor for a private placement of approximately $400,000,000 of ordinary shares (or equivalents). Shares funded in U.S. dollars, USDT or USD Coin are priced at $5.00, and shares funded in RAIN tokens are priced at $6.00, representing premiums of 17.4% and 40.8%, respectively, to the July 27, 2026 closing price.
The investor has currently elected to fund the purchase in RAIN tokens, which may be changed before closing. Enlivex plans to use net proceeds to advance its Rain protocol-based treasury strategy and its clinical-stage immunotherapy Allocetra™, focused on age-related osteoarthritis. The agreement grants Enlivex a discretionary right, for 36 months post-closing, to require the investor to purchase up to an additional $400,000,000 of securities on the same pricing terms. Closing is subject to shareholder approval under Nasdaq Listing Rules 5635(a), 5635(b) and Section 274 of the Israeli Companies Law, after which Enlivex expects to consummate the Transaction.
Enlivex (Nasdaq: ENLV) reported updated treasury metrics tied to its RAIN token holdings. As of July 18, 2026, net asset value (NAV) per ordinary share was $66.16, and the company held 79,550,593,122 RAIN tokens valued at approximately $1.1 billion, based on closing prices on CoinMarketCap.
According to Enlivex, these figures are unaudited mark-to-market valuations and are available on its online treasury dashboard. The company couples its clinical-stage Allocetra immunotherapy programs in age-related osteoarthritis with a prediction markets treasury strategy centered on the Rain protocol.
Enlivex (Nasdaq: ENLV) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™, its clinical-stage immunotherapy for age-related symptomatic primary knee osteoarthritis in patients aged 64 and older. RMAT status is intended to accelerate development of regenerative therapies that show preliminary evidence of addressing unmet medical needs in serious conditions.
According to Enlivex, RMAT designation enables intensive, early FDA interaction and potential eligibility for accelerated approval and priority review. The designation was based on a completed Phase I/IIa trial in which Allocetra™ showed statistically significant and clinically meaningful improvements in knee pain and physical function versus placebo, with durable efficacy for at least six months. Enlivex has initiated a randomized, controlled Phase IIb trial in the U.S. and EU, targeting 182 patients in this age group, and expects top-line data by the end of Q2 2027. The FDA has requested a Type B meeting to discuss the Allocetra™ program and align on Phase IIb and pivotal development plans.